Stockscreener 앱 받기
63.66
0.16%
0.10
시간 외 거래:
63.45
-0.21
-0.33%
전일 마감가:
$63.56
열려 있는:
$64.31
하루 거래량:
1.13M
Relative Volume:
0.57
시가총액:
$7.51B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
21.08
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-5.51%
1개월 성능:
-19.86%
6개월 성능:
-17.22%
1년 성능:
+4.26%
1일 변동 폭
$63.22
$64.58
1주일 범위
$63.22
$68.40
52주 변동 폭
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
63.66 | 7.51B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility - simplywall.st
Halozyme Therapeutics Receives 'Hold' Rating from Analysts - National Today
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness - finance.yahoo.com
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - simplywall.st
Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India
Halozyme names David Ramsay as interim CFO - Investing.com South Africa
Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma
Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com
Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus
Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus
Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PR Newswire
Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com
Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Halozyme Therapeutics COO Sells $599,000 in Shares - National Today
Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 20,000 Shares of Stock - MarketBeat
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery By Investing.com - Investing.com Canada
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery - Investing.com
Halozyme (HALO) COO exercises 21,546 options and sells 28,857 shares - Stock Titan
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewswire Inc.
Rule 144 sale notice: HALO (NASDAQ: HALO) 20,000 shares via option exercise - Stock Titan
Neo Ivy Capital Management Reduces Stake in Halozyme Therapeutics - National Today
Neo Ivy Capital Management Cuts Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Victory Capital Management Trims Halozyme Therapeutics Stake - National Today
Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment - marketscreener.com
Drug combo for relapsed or refractory myeloma cuts progression or death risk 83% - Stock Titan
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case - ChartMill
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' (HALO) Investment Narrative? - Sahm
Snyder Capital Management L P Sells 663,853 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Shares Sold by Investment Firm - National Today
Halozyme Therapeutics, Inc. $HALO Shares Sold by GW&K Investment Management LLC - MarketBeat
Cresset Asset Management LLC Reduces Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,393,800.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock - MarketBeat
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback - finance.yahoo.com
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Halozyme Therapeutics (HALO) Valuation Check As Recent Share Pullback Follows Strong Multi Year Returns - Yahoo Finance
Segall Bryant & Hamill LLC Sells 94,261 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Fisher Asset Management Boosts Stake in Halozyme Therapeutics - National Today
Fisher Asset Management LLC Purchases 29,147 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Earnings History & Surprises | EPS & Revenue Results | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme at TD Cowen Health Care Conference: Strategic Growth Insights - Investing.com
Halozyme Therapeutics (HAM:RV7) Total Operating Expense : €318 Mil (TTM As of Dec. 2025) - GuruFocus
Halozyme Therapeutics Sees Increased Investment from Handelsbanken Fonder AB - National Today
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 10 '26 |
Option Exercise |
33.51 |
1,546 |
51,806 |
15,912 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 09 '26 |
Sale |
67.80 |
20,000 |
1,356,072 |
14,366 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER |
Mar 10 '26 |
Sale |
67.64 |
8,857 |
599,087 |
7,055 |
0.48%
1.21%
자본화:
|
볼륨(24시간):